Title
Category
Credits
Event date
Cost
At the Forefront of Care for Patients with Worsening Heart Failure: New and Emerging Treatment Options
  • CMHC
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Welcome to our webcast on worsening heart failure. Heart failure remains one of the most challenging conditions to manage, with worsening heart failure being a critical area where suboptimal outcomes persist. While foundational therapies such as beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists, and ARNIs remain integral to heart failure management, advances in our understanding of heart failure pathophysiology have opened the door to newer, innovative therapeutic options, such as SGLT-2i, sCG stimulators and SGLT1/2 inhibitors.
Addressing the Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex condition rooted in metabolic disturbances and often coexists with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. Stemming from metabolic dysfunction-associated steatotic liver disease (MASLD), MASH is closely linked to cardiometabolic risk factors and pre-existing cardiovascular conditions. MASH is a gradually advancing and often asymptomatic liver disease that necessitates early detection and diagnosis.

Pages